PDS Biotechnology Corp. Stock
PDS Biotechnology Corp. Stock price
Key metrics
| Market capitalization | $52.43m |
| Enterprise Value | $32.57m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.31 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-36.32m |
| Free Cash Flow (TTM) Free Cash Flow | $-35.06m |
| Cash position | $41.69m |
Is PDS Biotechnology Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
PDS Biotechnology Corp. Stock Analysis
Analyst Opinions
3 Analysts have issued a PDS Biotechnology Corp. forecast:
Analyst Opinions
3 Analysts have issued a PDS Biotechnology Corp. forecast:
Financial data from PDS Biotechnology Corp.
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.06 -0.06 |
67%
67%
|
|
| EBITDA | -36 -36 |
15%
15%
|
EBIT (Operating Income) EBIT | -36 -36 |
16%
16%
|
| Net Profit | -38 -38 |
12%
12%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about PDS Biotechnology Corp. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PDS Biotechnology Corp. Stock News
Company Profile
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
| Head office | United States |
| CEO | Frank Bedu-Addo |
| Employees | 24 |
| Founded | 2005 |
| Website | www.pdsbiotech.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
